More articles about Merck | Wall St. Cheat Sheet

June 07, 2013

Is Pfizer a Buy at These Prices?

Pfizer is a biopharmaceutical company that attempts to improve lives through its research and development of medicines for people and animals around the world. The stock has been on a powerful run over the last several years but may be currently taking a breather.

May 31, 2013

Can Abbott Laboratories Maintain the Lead?

Abbott Laboratories provides essential and non-essential healthcare products to consumers and growing countries around the world. The stock is currently on a powerful run that has taken it to all-time high prices.

May 29, 2013

Not Every Blue Chip Loves Tuesdays

Even though the Dow has climbed higher for the past 20 Tuesdays, there is not one blue chip in the index with the same record...

May 25, 2013

Pfizer’s Setback and 5 Top Stories Affecting Dow Healthcare Stocks This Week

UnitedHealthcare Community Plan has enlarged its New York State government-sponsored health insurance programs to include 13 more counties in the Hudson Valley, and the Capital and Central New York regions.

May 22, 2013

Is Merck a Buy at These Prices?

Merck provides essential healthcare products to consumers, animals, and companies around the world. The stock has done well in recent years but is still part of a long-term downtrend.

May 21, 2013

Radar Movers: Saks Surges 18%, Apple Chats With Congress About Taxes

Analysis on highly active stocks for investors...

May 19, 2013

Johnson & Johnson and Merck Lead the Dow Healthcare Stock Rollercoaster Ride This Week

The UnitedHealthcare Children’s Foundation requests grant applications from families who require financial assistance to help pay for their children's health care treatments!

May 11, 2013

Should You Own Pfizer Stock?

Pfizer provides valuable products for the health, wellness, and support of people and animals living in a multitude of countries around the world. The stock has been a strong performer in recent years and looks to have a strong uptrend intact.

May 01, 2013

Can Merck Investors Look Beyond This Quarter’s Miss?

Merck's first-quarter results were severely affected by the 75 percent decrease in Singulair sales...

April 19, 2013

Is Pfizer a Good Defensive Play?

Pfizer has been a strong performer over the past year. Is this trend likely to continue?

April 15, 2013

Will These Safe Stocks Let the Cautious Join the Rally?

Following the 2008 collapse of world markets, the most cautious investors have been reluctant to get back into the stock game. Still, analysts see income potential in stocks that are relatively impervious to change...

April 13, 2013

3 Health Stocks That Ended The Week On A Bad Note

A couple of drug companies have grim outlooks thanks to patents expiring on popular drugs, while one company's innovation has come under heavy scrutiny. All three face tough times ahead...

April 10, 2013

Toyota Tosses Ford’s Claim and 4 Other Hot Stocks

Headlines you need to know this morning…

April 06, 2013

Buzzworthy Catalysts Giving Juice to Dow 30 Healthcare Stocks This Week

These stocks are moving the Dow this week...

April 05, 2013

Can This Business Help Pfizer in Emerging Markets?

Pfizer will not be divesting its $3.2 billion-a-year consumer health unit...

April 03, 2013

Pfizer Partners With Tetragenetics and 2 Dow Movers To Follow Today

These stocks are moving the Dow now...

March 15, 2013

Here’s Another Regulatory Hoop for Merck to Jump Through

Merck’s experimental medicine to reverse the effects of anesthesia -- sugammadex -- is currently bogged down by regulatory proceedings...

March 14, 2013

Is This FDA Investigation Bad News for Drug Makers?

Diabetes drugs from Merck, Bristol-Myers Squibb, and Novo Nordisk are under FDA scrutiny...

March 14, 2013

Can Merck Keep Growing?

Merck engages in a healthcare field that is seeing drastic changes in the coming years. Due to the increasing life expectancy of people worldwide, the company is in an area that can see significant profits. On the price chart, the stock hasn't performed too well but it looks to be getting ready to move higher. However, this move many not be supported by the disappointing earnings and revenue growth rates. Lastly, relative to its peers and sector, the stock has been a performance leader.